Pharmacological Strategies to Improve Bone Density in Functional Hypothalamic Amenorrhea

Overview

This systematic review and network meta-analysis evaluated pharmacological interventions to improve bone mineral density (BMD) in women with functional hypothalamic amenorrhea (FHA). Transdermal hormone replacement therapy (HRT) and teriparatide were found to significantly improve lumbar spine BMD, with transdermal HRT also benefiting femoral neck BMD. Oral HRT and combined oral contraceptive pills (COCP) showed no significant BMD improvement.

Background

Functional hypothalamic amenorrhea (FHA) is a common reproductive disorder causing estrogen deficiency that leads to low bone mineral density and increased fracture risk. Lifestyle interventions aiming to restore menses often fail, necessitating pharmacological treatment to preserve bone health. Estrogen deficiency in FHA impairs peak bone mass accrual and bone microarchitecture, with 44% of affected women exhibiting low BMD and fracture risk elevated 2-7 fold. Pharmacological options include hormone replacement therapies and anabolic agents, but comparative efficacy remains unclear.

Data Highlights

Key Findings

• Transdermal HRT significantly improves lumbar spine and femoral neck BMD in women with FHA.
• Teriparatide shows superior efficacy over transdermal HRT and COCP for lumbar spine BMD but not for femoral neck or total hip BMD.
• Oral HRT and combined oral contraceptive pills do not significantly improve BMD at any measured site.
• Pharmacological interventions are considered when lifestyle modifications fail to restore menses and bone health.
• International guidelines recommend transdermal HRT as first-line pharmacotherapy for bone health in FHA, despite low certainty evidence.
• Antiresorptive agents like bisphosphonates and denosumab are not recommended in reproductive-age women due to safety concerns.

Clinical Implications

Clinicians should prioritize transdermal HRT to improve bone density in women with FHA who do not respond to lifestyle interventions. Teriparatide may be considered in selected cases with severe bone loss, although typically reserved for short-term use. Oral HRT and COCP should not be relied upon for bone health improvement in this population. Careful patient selection and monitoring are essential given the limited high-certainty evidence.

Conclusion

Transdermal hormone replacement therapy and teriparatide effectively improve lumbar spine bone mineral density in women with functional hypothalamic amenorrhea, with transdermal HRT also benefiting femoral neck BMD. These findings support current guideline recommendations favoring transdermal HRT as first-line pharmacotherapy for bone health in FHA.

References

1. Systematic Review and Network Meta-Analysis (2025) -- Pharmacological Strategies for Enhancing Bone Density in Functional Hypothalamic Amenorrhea